Latest stories on FATE
Fate Therapeutics announces clinical data from FT819 study
The Fly59 · neutralproduct/pr
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
Business Insider56 · neutralgeneral
Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead
Seeking Alpha63 · neutralproduct/pr
Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial
TipRanks63 · neutralproduct/pr
Fate Therapeutics reports Q2 EPS (25c), consensus (26c)
The Fly48 · neutralearnings
Fate Therapeutics price target raised to $3.50 from $2.50 at Wells Fargo
The Fly61 · neutralanalyst
Fate Therapeutics intiates first patient in RECLAIM-LN trial
The Fly56 · neutralproduct/pr
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
StockTitan63 · neutralproduct/pr
Fate Therapeutics GAAP EPS of -$0.25 beats by $0.02, revenue of $2.08M beats by $0.81M
Seeking Alpha56 · neutralearnings
FATE THERAPEUTICS INC (FATE) files 8-K
SEC 8-K50 · neutralgeneral
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
GlobeNewswire56 · neutralearnings
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Business Insider56 · neutralearnings
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
S&P 500, Nasdaq, Dow End Higher Led By Chipmaker Stocks As Investors Look Past US-Iran Hostility — ORCL, SBUX, WULF, PANW, FATE In Focus
Stocktwits News58 · neutralgeneral
FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials
Stocktwits News67 · bullishproduct/pr
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate | FATE Stock News
StockTitan67 · bullishproduct/pr
Fate Therapeutics: There Is A Bull Case, But It's Going To Take Time To Develop (Rating Downgrade)
Seeking Alpha56 · neutralproduct/pr
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences | FATE Stock News
StockTitan55 · neutralgeneral
Fate Therapeutics: FT819 Progress Keeps My Bull Case Alive
Seeking Alpha63 · neutralproduct/pr
FATE THERAPEUTICS INC (FATE) files 8-K
SEC 8-K50 · neutralgeneral
Fate Therapeutics Appoints Laura Hamill to Board of Directors | FATE Stock News
StockTitan55 · neutralgeneral
Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline
TipRanks63 · neutralproduct/pr